Journal of Intellectual Property Rights

Open Access Open Access  Restricted Access Subscription Access

Rethinking the Role of Intellectual Property Rights in Pharmaceutical Industry of Saudi Arabia


Affiliations
1 College of Business and Administration, Princess Nourahbint Abdulrahman University, Riyadh, Saudi Arabia., Saudi Arabia
 

This article attempts to analyze the role of pharmaceutical industry intellectual property rights and comparison of Saudi Arabia with other watch list and non-watch list countries according to the US trade representative Special 301 Report. Time series data (2001-2020) is used to compare and analyze the data using simple regression. Also, Covariance analysis and least square method are used to compare the data of other countrieswith Saudi Arabia. It was found that there is significant impact of the Saudi pharmaceutical industry on the GDP, and ithas also developed its IPRs, patents, trademarks, and trade secrets. Macroeconomic outcomes are strongly tied to the enforcement of IP laws in both watch list and non-watch list countries. Therefore, it is important to underline the differences in IPR in these countries. This will help us to test whether empirical results at macro-level -that are alleged to be led by the stronger or weak IP laws – holdin the actual IP Law enforcements. In this paper, we investigate the differences and similaritiesin IP laws in these selected countries.

Keywords

Pharmaceutical Industry, Intellectual Property Rights, GDP, IP Laws, Special 301 Report, Watch-List, Non-Watch-List Countries, Patents, Trademarks, National Transformation Program (NTP) 2020.
User
Notifications
Font Size

  • Anonymous, Research and development in Industry: An overview New Delhi: Department of Scientific and Industrial Research, Government of India, (2002).

  • Glasgow L J, Stretching the limits of intellectual property rights: Has the pharmaceutical industry gone too far? Journal of Law and Technology, 41 (2007) 227–58.

  • Angell M, The pharmaceutical industry, To whom is it accountable? The New England Journal of Medicine, 342 (2000) 1902–4.

  • Kartal M, Intellectual property protection in the natural product drug discovery, traditional herbal medicine, and herbal medicinal products, National Library of Medicine, 21 (2007) 113–9.

  • Lexchin J, Intellectual property rights and the Canadian pharmaceutical marketplace: Where do we go from here? International Journal of Health Services, 35 (2005) 237–56.

  • Mrudula B S, Durgadevi N K, Madhavi B R, Tejeswi B & Durga P V, Intellectual property rights pinpoint at IPR spotlights coveted R and D, Drug India Today, 2 (2009) 197–201.

  • Pharma Boardroom Legal Articles Legal and Regulatory Patents And Trademarks 2020, KSA (2020).

  • Abbott F M, Cottier T & F Gurry, International Intellectual Property in an Integrated world economy, ASPEAN Publishing, (4) (2009).

  • David P A, Intellectual Property Institutions and the Panda's Thumb: Patents, Copyrights, and Trade Secrets in Economic Theory and History, National Academies of Sciences, Engineering, and Medicine. Global Dimensions of Intellectual Property Rights in Science and Technology, National Academy Press,Washington, DC (1993).

  • WIPO Magazine, Intellectual property, innovation access and Covid-19-WIPO, Legal Article-008, (2020).

  • Mac Donald S, Globalization offood and Agriculture and the Poor, Oxford University Press,(2001).

  • Heller M A & Eisenburg R S, (1998) Can Patents deter innovation? The anti-commons in Biomedical research, Springer Dordrecht, 2005, 698-701.


Abstract Views: 73

PDF Views: 85




  • Rethinking the Role of Intellectual Property Rights in Pharmaceutical Industry of Saudi Arabia

Abstract Views: 73  |  PDF Views: 85

Authors

Puja Sunil Pawar
College of Business and Administration, Princess Nourahbint Abdulrahman University, Riyadh, Saudi Arabia., Saudi Arabia
Ghadah Alarifi
College of Business and Administration, Princess Nourahbint Abdulrahman University, Riyadh, Saudi Arabia., Saudi Arabia

Abstract


This article attempts to analyze the role of pharmaceutical industry intellectual property rights and comparison of Saudi Arabia with other watch list and non-watch list countries according to the US trade representative Special 301 Report. Time series data (2001-2020) is used to compare and analyze the data using simple regression. Also, Covariance analysis and least square method are used to compare the data of other countrieswith Saudi Arabia. It was found that there is significant impact of the Saudi pharmaceutical industry on the GDP, and ithas also developed its IPRs, patents, trademarks, and trade secrets. Macroeconomic outcomes are strongly tied to the enforcement of IP laws in both watch list and non-watch list countries. Therefore, it is important to underline the differences in IPR in these countries. This will help us to test whether empirical results at macro-level -that are alleged to be led by the stronger or weak IP laws – holdin the actual IP Law enforcements. In this paper, we investigate the differences and similaritiesin IP laws in these selected countries.

Keywords


Pharmaceutical Industry, Intellectual Property Rights, GDP, IP Laws, Special 301 Report, Watch-List, Non-Watch-List Countries, Patents, Trademarks, National Transformation Program (NTP) 2020.

References